Clinical Trial Update: Bioequivalence Studies of Dasatinib 100 Mg [Phase 4]

View source ↗

Summary

Phase 4 bioequivalence study of dasatinib 100 mg for multiple myeloma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Centro de Atencion e Investigacion Medica | Conditions: Myeloma Multiple | Phase 4 | Status: NOT_YET_RECRUITING